At a preclinical level, in vitro and in vivo, Cebiotex has developed and characterised nonwoven nanofibre membranes for local delivery of active ingredients for local treatment of the surgical bed following tumour removal surgery.
The purpose of local drug delivery is to achieve high concentrations of active ingredients in the area where the delivery device is placed. This prevents systemic toxicity and increases the efficacy of the drug against potential residual tumour.
External innovation (Universitat Politècnica de Catalunya). Cebiotex is the first spin-off resulting from interaction between researchers from two Catalan institutions, Universitat Politècnica de Catalunya (UPC) and SJD Barcelona Children's Hospital.
- Worldwide patent.
- Company founded (2013).
- Clinical trial (2015).